Compare Nirsevimab to Palivizumab for RSV Prevention
October 2023
You’ll hear buzz about nirsevimab-alip (Beyfortus) to prevent respiratory syncytial virus (RSV) in young children.
RSV is the most common cause of hospitalization in US infants...and typically circulates from October through March. Almost 8 in 10 kids under age 2 who get hospitalized for RSV are otherwise healthy.
Nirsevimab is a monoclonal antibody given IM in the hospital or clinic...similar to palivizumab (Synagis). But nirsevimab has a broader indication...palivizumab is only for certain high-risk kids.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote